Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
13 May 2021 - 3:05AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced that, based on a preliminary vote count
provided by its proxy solicitors following its 2021 Annual Meeting
of Stockholders, stockholders have voted to re-elect all three of
Adverum’s highly qualified director nominees – Dawn Svoronos, Reed
V. Tuckson, M.D. and Thomas Woiwode, Ph.D. – to the Adverum Board
of Directors, ratified the selection of Ernst & Young LLP as
independent auditors and approved, on an advisory basis, the
compensation of Adverum’s named executive officers.
Adverum issued the following statement:
The Adverum Board and management team appreciate the support of
our stockholders and the constructive feedback we received
throughout this process. We are encouraged that stockholders
recognize the strength of our Board, management team and strategy
to drive Adverum forward. Adverum is laser focused on conducting a
thorough review of data from the ADVM-022 program, and patient
safety remains its top priority.
The results of the vote announced today are considered
preliminary until final results are tabulated and certified by the
independent Inspector of Elections. Final results will be reported
on a Form 8-K that will be filed with the U.S. Securities and
Exchange Commission.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene
therapy company targeting unmet medical needs in serious ocular and
rare diseases. Adverum is advancing the clinical development of its
novel gene therapy candidate, ADVM-022, as a one-time, intravitreal
injection for the treatment of patients with wet age-related
macular degeneration and diabetic macular edema. For more
information, please visit www.adverum.com.
Investor Relations Contact
Myesha Lacy Vice President, Investor Relations and Corporate
Communications Adverum Biotechnologies, Inc. T: 650-649-1257 E:
mlacy@adverum.com
Or
Scott Winter / Gabrielle Wolf Innisfree M&A Incorporated T:
212-750-5833
Media Contact
Andrea Cohen Sam Brown Inc. T: 917-209-7163 E:
andreacohen@sambrown.com
Or
Dan Moore Joele Frank, Wilkinson Brimmer Katcher T:
212-355-4449
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2024 to May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From May 2023 to May 2024